Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29039546 | 0.88 | ALDH1A1 (0.60) | ALDH1A1GAAL3MBTL1ACHENPSR1 | |
| SCHEMBL7457094 | 0.87 | KCNA3 (0.52) | ALDH1A1GAAL3MBTL1NPSR1LMNA | |
| SCHEMBL29080842 | 0.86 | ALDH1A1 (0.58) | ALDH1A1GAAL3MBTL1ACHENPSR1 | |
| SCHEMBL257604 | 0.85 | HTT (0.45) | ALDH1A1GAAL3MBTL1NPSR1LMNA | |
| SCHEMBL8737442 | 0.81 | SLC6A4 (0.49) | ALDH1A1GAAL3MBTL1NPSR1LMNA | |
| SCHEMBL10597815 | 0.81 | KCNA3 (0.51) | ALDH1A1GAAL3MBTL1NPSR1LMNA | |
| SCHEMBL16920391 | 0.81 | CYP1A2 (0.52) | ALDH1A1GAAL3MBTL1LMNAKCNA3 | |
| SCHEMBL5503879 | 0.81 | AR (0.62) | ALDH1A1GAAL3MBTL1AR | |
| SCHEMBL29860318 | 0.81 | KCNA3 (0.58) | ALDH1A1GAAL3MBTL1NPSR1LMNA | |
| SCHEMBL441860 | 0.81 | KCNA3 (0.58) | ALDH1A1GAAL3MBTL1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065357-B1 | Improved process for the catalytic synthesis of diaryl ethers | SALTIGO GMBH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-8304550-B2 | Process for the catalytic synthesis of diaryl ethers | SALTIGO GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304550-B2 | Process for the catalytic synthesis of diaryl ethers | SALTIGO GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090143594-A1 | PROCESS FOR THE CATALYTIC SYNTHESIS OF DIARYL ETHERS | SALTIGO GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143594-A1 | PROCESS FOR THE CATALYTIC SYNTHESIS OF DIARYL ETHERS | SALTIGO GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| EP-2065356-A1 | Improved process for the catalytic synthesis of diaryl ethers | Saltigo GmbH (DE) | 2009-06-03 | — | — | EP | disclosed |
| EP-2065357-A1 | Improved process for the catalytic synthesis of diaryl ethers | Saltigo GmbH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | ALDH1A1 3163/4885GAA 1663/4885L3MBTL1 3967/4885 |
| US-20090143594-A1 | PROCESS FOR THE CATALYTIC SYNTHESIS OF DIARYL ETHERS | ARSA, AHR, AOC2 | ALDH1A1 282/4885GAA 1702/4885L3MBTL1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.